Skip to main content
Premium Trial:

Request an Annual Quote

Spectral Genomics Licenses Affy Patents for Diagnostic Use

NEW YORK, March 2 (GenomeWeb News) - Spectral Genomics of Houston, Texas, said yesterday that it has agreed to license certain Affymetrix patents to manufacture and sell spotted DNA arrays for use in the diagnostics market.

The agreement will commence "once the necessary regulatory approvals of Spectral Genomics' products have been obtained," the company said.

The license agreement covers Spectral Genomics' Constitutional Chip, slated to be introduced in 2004, as well as additional anticipated specialty arrays to be used in cancer diagnostics.

The company already sells these chips as research products under a licensing agreement it signed with Affy in October. The new agreement pertains to Spectral Genomics' plans to seek regulatory approval for these products as diagnostics.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.